Working... Menu
Trial record 93 of 112 for:    mf59

Safety and Immunogenicity of an Adjuvanted Influenza Vaccine in Subjects Aged 65 Years and Over.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00316628
Recruitment Status : Completed
First Posted : April 21, 2006
Last Update Posted : September 14, 2006
Novartis Vaccines
Information provided by:

Brief Summary:
The purpose of this study is to evaluate safety and immunogenicity of a single intramuscular (IM) injection of an adjuvanted influenza vaccine in elderly subjects.

Condition or disease Intervention/treatment Phase
Influenza Biological: influenza vaccine Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 50 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated, (Adjuvanted With MF59C.1) Influenza Vaccine, Formulation 2005-2006, When Administered to Elderly Subjects.
Study Start Date : June 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Flu Flu Shot

Primary Outcome Measures :
  1. CHMP criteria for evaluation of flu vaccines e.g Seroprotection, GMR's and Seroconversion rate at day 21 following vaccination.

Secondary Outcome Measures :
  1. Number and percentage of subjects with at least one local reaction between Day 0 and Day 3 after vaccine injection.
  2. Number and percentage of subjects with at least one systemic reaction between Day 0 and Day 3 after vaccine injection.
  3. Number and percentage of subjects with at least one adverse event between Day 0 and the study termination visit (Day 21, window: 20-24).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   65 Years and older   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 65 years of age or older and in good health

Exclusion Criteria:

  • Any serious disease such as: cancer, autoimmune disease, advanced arteriosclerotic disease or complicated diabetes mellitus, chronic obstructive pulmonary disease (COPD) that requires oxygen therapy, acute or progressive hepatic disease, acute or progressive renal disease, congestive heart failure.
  • any acute disease or infections requiring systemic antibiotic or antiviral therapy
  • hypersensitivity to eggs, chicken protein, chicken feathers, influenza viral protein, neomycin or polymyxin or any other component of the vaccine
  • history of neurological symptoms or signs, or anaphylactic shock following administration of any vaccine
  • known or suspected (or high risk of developing) impairment/alteration of immune function within the past 7 days

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00316628

Layout table for location information
G. D'Annunzio University
Chieti, Italy, 66100
Office of Hygiene and Public Health, ASL Lanciano
Lanciano, Italy
Sponsors and Collaborators
Novartis Vaccines
Layout table for investigator information
Study Director: Novartis Vaccines - Drug Information Services Novartis

Layout table for additonal information Identifier: NCT00316628     History of Changes
Other Study ID Numbers: V70P3S
Eudract number: 2005-000621-38
First Posted: April 21, 2006    Key Record Dates
Last Update Posted: September 14, 2006
Last Verified: September 2006

Keywords provided by Novartis:

Additional relevant MeSH terms:
Layout table for MeSH terms
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases
Immunologic Factors
Physiological Effects of Drugs